Halozyme Therapeutics, Inc.
HALONASDAQHealthcare● Active
$71.53
$-0.07(-0.10%)
Market Cap$8.5B
P/E Ratio—
52W High$82.22
52W Low$51.06
Halozyme Therapeutics, Inc. (HALO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HALO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
$1.60
Est. $1.55 · +3.2%
Revenue
$0.38B
Est. $0.36B · +5.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
HALO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.00
Rev. $0.01B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.00
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $1.82 | — | — | — | $0.40B | — |
| ▲ Q2 FY2026 | May 11, 2026 | $1.55 | $1.60 | +3.2% | $0.38B | $0.36B | +5.0% |
| ▼ Q1 FY2026 | Feb 17, 2026 | $2.15 | -$0.24 | -111.2% | $0.45B | $0.44B | +3.7% |
| ▲ Q4 FY2025 | Nov 3, 2025 | $1.63 | $1.72 | +5.5% | $0.35B | $0.45B | -20.7% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $1.23 | $1.54 | +25.2% | $0.33B | $0.33B | -1.5% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.95 | $1.11 | +16.8% | $0.26B | $0.28B | -5.7% |
| ▲ Q1 FY2025 | Feb 18, 2025 | $1.17 | $1.26 | +7.7% | $0.30B | $0.29B | +4.3% |
| ▲ Q4 FY2024 | Oct 31, 2024 | $0.98 | $1.27 | +29.6% | $0.29B | $0.29B | -0.9% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$1.82
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
$1.60
EPS Est.
$1.55
EPS Surpr.
+3.2%
Revenue
$0.38B
Q1 FY2026
Feb 17, 2026Miss
EPS Actual
-$0.24
EPS Est.
$2.15
EPS Surpr.
-111.2%
Revenue
$0.45B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
$1.72
EPS Est.
$1.63
EPS Surpr.
+5.5%
Revenue
$0.35B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$1.54
EPS Est.
$1.23
EPS Surpr.
+25.2%
Revenue
$0.33B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$1.11
EPS Est.
$0.95
EPS Surpr.
+16.8%
Revenue
$0.26B
Q1 FY2025
Feb 18, 2025Beat
EPS Actual
$1.26
EPS Est.
$1.17
EPS Surpr.
+7.7%
Revenue
$0.30B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
$1.27
EPS Est.
$0.98
EPS Surpr.
+29.6%
Revenue
$0.29B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.49 | $2.62 | $2.73 | 2 |
| Q3 FY2027 | $2.42 | $2.54 | $2.65 | 1 |
| Q2 FY2027 | $2.36 | $2.48 | $2.59 | 1 |
| Q1 FY2027 | $2.15 | $2.26 | $2.35 | 2 |
| Q4 FY2026 | $2.41 | $2.53 | $2.63 | 2 |
| Q3 FY2026 | $2.08 | $2.18 | $2.29 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.5B | $0.5B | $0.6B | 2 |
| Q3 FY2027 | $0.5B | $0.5B | $0.5B | 2 |
| Q2 FY2027 | $0.5B | $0.5B | $0.5B | 2 |
| Q1 FY2027 | $0.4B | $0.5B | $0.5B | 2 |
| Q4 FY2026 | $0.5B | $0.5B | $0.5B | 2 |
| Q3 FY2026 | $0.5B | $0.5B | $0.5B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +3.2% | $64.12 | $66.41 | +3.57% |
| ▼ Q1 FY2026 | Feb 17, 2026 | -111.2% | $79.44 | $80.48 | +1.31% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +5.5% | $65.19 | $66.20 | +1.55% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +25.2% | $59.99 | $60.81 | +1.37% |
| ▲ Q2 FY2025 | May 6, 2025 | +16.8% | $60.62 | $59.38 | -2.05% |
| ▲ Q1 FY2025 | Feb 18, 2025 | +7.7% | $58.29 | $57.90 | -0.67% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +29.6% | $50.59 | $50.57 | -0.04% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +19.7% | $52.11 | $51.94 | -0.33% |
Q2 FY2026+3.57%
Report Date
May 11, 2026
EPS Beat/Miss
+3.2%
Price Before
$64.12
Price After
$66.41
Q1 FY2026+1.31%
Report Date
Feb 17, 2026
EPS Beat/Miss
-111.2%
Price Before
$79.44
Price After
$80.48
Q4 FY2025+1.55%
Report Date
Nov 3, 2025
EPS Beat/Miss
+5.5%
Price Before
$65.19
Price After
$66.20
Q3 FY2025+1.37%
Report Date
Aug 5, 2025
EPS Beat/Miss
+25.2%
Price Before
$59.99
Price After
$60.81
Q2 FY2025-2.05%
Report Date
May 6, 2025
EPS Beat/Miss
+16.8%
Price Before
$60.62
Price After
$59.38
Q1 FY2025-0.67%
Report Date
Feb 18, 2025
EPS Beat/Miss
+7.7%
Price Before
$58.29
Price After
$57.90
Q4 FY2024-0.04%
Report Date
Oct 31, 2024
EPS Beat/Miss
+29.6%
Price Before
$50.59
Price After
$50.57
Q3 FY2024-0.33%
Report Date
Aug 6, 2024
EPS Beat/Miss
+19.7%
Price Before
$52.11
Price After
$51.94
Avg Beat Reaction+0.49%
Avg Miss Reaction+1.31%
Beat Rate7 / 8 quarters
Largest Move+3.57% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HALO ends December
Halozyme Therapeutics, Inc. (HALO) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $1.60 — beating the analyst consensus of $1.55 by +3.2%. The next HALO earnings date is expected around September 1, 2026.
Each quarter, investors track HALO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HALO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HALO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HALO earnings · 5 questionsHalozyme Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. HALO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HALO historically reports after market close (AMC).
HALO earnings datewhen is HALO earningsHALO next earnings datewhen does HALO report earningsHALO earnings calendar
▸ Source: FMP · Halozyme Therapeutics, Inc. SEC filings · US GAAP · Halozyme Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026